Skip Nav Destination
Drug Discovery
Drug Discovery for Schizophrenia: From PNS to CNS and Back
Edited by
Tatiana V Lipina
Tatiana V Lipina
University of Toronto, Canada
Search for other works by this author on:
Print ISSN:
2041-3203
Hardback ISBN:
978-1-83767-205-9
EPUB ISBN:
978-1-83767-693-4
PDF ISBN:
978-1-83767-746-7
Special Collection:
2024 eBook Collection
Series:
Drug Discovery Series
No. of Pages:
264
Publication date:
06 Dec 2024
About this book
Following progress in schizophrenia since 2015, this new volume covers the advancing knowledge of scientists and clinicians in drug discovery. The book enhances our understanding of pathological neural communication between the peripheral nervous system (PNS) and central nervous system (CNS) in patients with schizophrenia. Although 75% of neural information passes through the PNS, interactions between the PNS and CNS in schizophrenia remain understudied. Consequently, the current view of schizophrenia requires improvement to facilitate diagnostics and drug development.
In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication). Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.
The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential. Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.
Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models.
Drug Discovery for Schizophrenia: From PNS to CNS and Back, Royal Society of Chemistry, 2024.
Download citation file:
Digital access
$235.00
Print format
Drug Discovery for Schizophrenia
$235.00
Table of contents
-
Chapter 1: Genetic Architecture of Schizophrenia: Transitioning from Candidate Genes to Polygenic Risk Scoresp1-18ByMahbod Ebrahimi;Mahbod EbrahimiaTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T1R8, CanadabInstitute of Medical Science, University of Toronto, CanadaSearch for other works by this author on:Niki Akbarian;Niki AkbarianaTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T1R8, CanadabInstitute of Medical Science, University of Toronto, CanadaSearch for other works by this author on:Kowsar Teymouri;Kowsar TeymouriaTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T1R8, CanadabInstitute of Medical Science, University of Toronto, CanadaSearch for other works by this author on:Arun K. Tiwari;Arun K. TiwariaTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T1R8, CanadabInstitute of Medical Science, University of Toronto, CanadacDepartment of Psychiatry, University of Toronto, CanadaSearch for other works by this author on:James L. Kennedy;James L. KennedyaTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T1R8, CanadabInstitute of Medical Science, University of Toronto, CanadacDepartment of Psychiatry, University of Toronto, CanadaSearch for other works by this author on:Clement C. ZaiClement C. ZaiaTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T1R8, Canada [email protected]bInstitute of Medical Science, University of Toronto, CanadacDepartment of Psychiatry, University of Toronto, CanadadLaboratory Medicine and Pathobiology, University of Toronto, CanadaeStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, USASearch for other works by this author on:
-
Chapter 2: Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discoveryp19-30ByJohn L. Waddington;John L. WaddingtonaSchool of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin D02 YN77, Ireland [email protected]bJiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psychiatric-Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, ChinaSearch for other works by this author on:Xuechu ZhenXuechu ZhenbJiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psychiatric-Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, ChinaSearch for other works by this author on:
-
Chapter 3: Combinatorial Behavioural Phenotyping of Mouse Models of Schizophreniap31-56ByTatiana V. LipinaTatiana V. LipinaUniversity of Toronto, Department of Pharmacology & Toxicology, Toronto, ON, Canada [email protected]Search for other works by this author on:
-
Chapter 4: Beyond Brain Boundaries: The Emerging Significance of Vagal Body-to-brain Communication in Schizophreniap57-79ByJean-Philippe Krieger;Jean-Philippe KriegeraInstitute of Neuroscience and Physiology, University of Gothenburg, Sweden [email protected]bInstitute of Veterinary Pharmacology and Toxicology, University of Zurich-Vetsuisse, SwitzerlandcNeuroscience Center Zurich, University of Zurich and ETH Zurich, SwitzerlandSearch for other works by this author on:Urs MeyerUrs MeyerbInstitute of Veterinary Pharmacology and Toxicology, University of Zurich-Vetsuisse, Switzerland [email protected]cNeuroscience Center Zurich, University of Zurich and ETH Zurich, SwitzerlandSearch for other works by this author on:
-
Chapter 5: Iron Dyshomeostasis in Schizophrenia and Potential Treatments to Mitigate Its Effectsp80-112ByS. OkaforS. OkaforUniversity of Toronto, Toronto, ON, Canada [email protected]Search for other works by this author on:
-
Chapter 6: Smell of Dopamine in Schizophrenia: Towards Drug Discoveryp113-132ByHai-Qian Zhou;Hai-Qian ZhouaKey Laboratory of Brain Functional Genomics, Ministry of Education and Shanghai, School of Life Science, East China Normal University, Shanghai 200062, ChinaSearch for other works by this author on:Qian Li;Qian LibSongjiang Hospital and Songjiang Research Institute, Shanghai Key Laboratory of Emotions and Affective Disorders, Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaSearch for other works by this author on:Dong-Min YinDong-Min YinaKey Laboratory of Brain Functional Genomics, Ministry of Education and Shanghai, School of Life Science, East China Normal University, Shanghai 200062, China [email protected]Search for other works by this author on:
-
Chapter 7: Aromatherapy: A Novel Approach to Schizophrenia Treatmentp133-155ByE. MerkulovaE. MerkulovaaScientific Research Institute of Neurosciences and Medicine, Novosibirsk, Russia [email protected]Search for other works by this author on:
-
Chapter 8: Emerging Non-invasive Brain Stimulations for Schizophreniap156-184ByXi-Yu Wang;Xi-Yu WangaInstitute for Medical Science, Temerty Faculty of Medicine, University of Toronto, CanadabCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, CanadaSearch for other works by this author on:Daniel M. Blumberger;Daniel M. BlumbergeraInstitute for Medical Science, Temerty Faculty of Medicine, University of Toronto, CanadabCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, CanadacTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, CanadadDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, CanadaSearch for other works by this author on:Plabon Ismail;Plabon IsmaileWaypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, CanadafDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, CanadaSearch for other works by this author on:Bernard Le FollBernard Le FollaInstitute for Medical Science, Temerty Faculty of Medicine, University of Toronto, CanadabCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, CanadacTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, CanadadDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, CanadaeWaypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, CanadagAddictions Division, Centre for Addiction and Mental Health, CanadahPoul Hansen Family Centre for Depression, Krembil Research Institute, Toronto Western Hospital, University Health Network, CanadaiDepartment of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, CanadajDepartment of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, CanadakInstitute of Mental Health Policy Research, Centre for Addiction and Mental Health, CanadalCAMH Mental Health Sciences Library, Department of Education, Centre for Addiction and Mental Health, Canada [email protected]Search for other works by this author on:
-
Chapter 9: From Circuits to Drug Targets: The Promise of Opto- and Chemogenetics for Drug Discoveryp185-224ByD. KätzelD. KätzelInstitute of Applied Physiology, Ulm University, Germany [email protected]Search for other works by this author on:
-
Chapter 10: Therapeutic Implications of Recent Genomic Discoveries in Schizophreniap225-241ByS. J. ClapcoteS. J. ClapcoteUniversity of Leeds, School of Biomedical Sciences, Woodhouse Lane, Leeds, LS2 9JT, UK [email protected]Search for other works by this author on:
Spotlight
Advertisement
Advertisement
